Development of a Web-Based Nomogram for Predicting Survival in Patients with Esthesioneuroblastoma Using SEER Database.
- 1Virginia Tech Carilion School of Medicine, Virginia Tech, Roanoke, VA 24016, USA.
- 2Translational Biology, Medicine, and Health Graduate Program, Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA 24016, USA.
- 3Department of Neurosurgery, Carilion Clinic, Roanoke, VA 24014, USA.
Abstract
Background: Esthesioneuroblastoma (ENB) is a rare neuroectodermal tumor arising from the olfactory epithelium. This study aimed to identify survival determinants and construct a prognostic web-based nomogram to provide individualized survival predictions for ENB patients. Methods: Patients diagnosed with ENB between 2000 and 2022 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Patient demographics, tumor characteristics, and treatment data were analyzed using Cox proportional hazards models and Kaplan-Meier survival curves. A web-based nomogram was constructed to predict 5- and 10-year survival probabilities individualized to a specific patient. Results: Nine hundred and forty-one ENB patients were analyzed. Overall survival (OS) rates at 1-, 2-, 5-, and 10-years were 89%, 85%, 75%, and 58%, respectively. Multivariable analysis revealed that age over 50 (p < 0.001) and tumor size over 6.0 cm (p < 0.01) were independent predictors of worse OS. Compared to patients treated with gross total resection (GTR) alone, worse OS was observed in those treated with chemotherapy (CT) only (p < 0.01), CT and radiation (RT, p < 0.01), GTR + CT (p < 0.05), RT only (p < 0.01), or no treatment (p < 0.001). No statistically significant differences in OS were found between GTR alone and GTR + RT, GTR + RT + CT, subtotal resection (STR), or STR with adjuvant therapies. The resulting ENB prognostic nomogram demonstrated acceptable predictive performance, with a C-index of 0.733 ± 0.041 and AUC of 0.749. Conclusions: Age and tumor size are critical survival determinants in ENB, and GTR continues to be the foundational treatment. The developed prognostic web-based nomogram successfully quantifies individualized survival probabilities, providing clinicians with a tailored tool to guide evidence-based counseling and management for ENB patients.
Related
- Development and internal validation of a nomogram for predicting short- and long-term overall survival in patients with breast cancer liver metastasis: a SEER-based prognostic study
- Development and validation of a nomogram for predicting 5-year progression-free survival probability in differentiated thyroid cancer patients with lung metastases
- Multi-model comparison and nomogram development for predicting in-hospital mortality in Trauma patients based on NLR and other indicators
- Development and internal validation of a nomogram for predicting mechanical ventilation requirement in adult tetanus patients: a dual-center retrospective study
- Development and validation of a novel metabolic-inflammatory health-related nomogram for predicting in-hospital mortality in older patients with type 2 diabetes mellitus combined with cardiovascular disease
BibTeX
@article{barbaro2026development,
title = {{Development of a Web-Based Nomogram for Predicting Survival in Patients with Esthesioneuroblastoma Using SEER Database.}},
author = {Julianna L Barbaro and Abhishek S Bhutada and Srijan Adhikari and Kristine Ravina and Eric A Marvin},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193145},
url = {https://europepmc.org/article/MED/42882839},
note = {CC BY},
}
RIS
TY - JOUR
TI - Development of a Web-Based Nomogram for Predicting Survival in Patients with Esthesioneuroblastoma Using SEER Database.
AU - Julianna L Barbaro
AU - Abhishek S Bhutada
AU - Srijan Adhikari
AU - Kristine Ravina
AU - Eric A Marvin
PY - 2026
DA - 2026/09/29
JO - Cancers
DO - 10.3390/cancers18193145
UR - https://europepmc.org/article/MED/42882839
AB - Background: Esthesioneuroblastoma (ENB) is a rare neuroectodermal tumor arising from the olfactory epithelium. This study aimed to identify survival determinants and construct a prognostic web-based nomogram to provide individualized survival predictions for ENB patients. Methods: Patients diagnosed with ENB between 2000 and 2022 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Patient demographics, tumor characteristics, and treatment data were analyzed using Cox proportional hazards models and Kaplan-Meier survival curves. A web-based nomogram was constructed to predict 5- and 10-year survival probabilities individualized to a specific patient. Results: Nine hundred and forty-one ENB patients were analyzed. Overall survival (OS) rates at 1-, 2-, 5-, and 10-years were 89%, 85%, 75%, and 58%, respectively. Multivariable analysis revealed that age over 50 (p < 0.001) and tumor size over 6.0 cm (p < 0.01) were independent predictors of worse OS. Compared to patients treated with gross total resection (GTR) alone, worse OS was observed in those treated with chemotherapy (CT) only (p < 0.01), CT and radiation (RT, p < 0.01), GTR + CT (p < 0.05), RT only (p < 0.01), or no treatment (p < 0.001). No statistically significant differences in OS were found between GTR alone and GTR + RT, GTR + RT + CT, subtotal resection (STR), or STR with adjuvant therapies. The resulting ENB prognostic nomogram demonstrated acceptable predictive performance, with a C-index of 0.733 ± 0.041 and AUC of 0.749. Conclusions: Age and tumor size are critical survival determinants in ENB, and GTR continues to be the foundational treatment. The developed prognostic web-based nomogram successfully quantifies individualized survival probabilities, providing clinicians with a tailored tool to guide evidence-based counseling and management for ENB patients.
SN - 2072-6694
ER -